All conditions Ozempic (semaglutide) treats or is studied for: type 2 diabetes, weight loss, heart disease, kidney disease, fatty liver (MASH), PCOS, prediabetes, heart failure, sleep apnea, osteoarthritis.
Ozempic program | Nepal treatment guide | FAQs | What is Ozempic? | Dosage | Who should avoid | Drug interactions | Monitoring | Results | Vs Wegovy vs Mounjaro | Diet & exercise | Price in Nepal | Stree Clinic | Lead Doctor | Weight loss | Diabetes care | Side effects | Success stories | Editorial policy | How to get Ozempic | Results timeline | Meal plan | Injection guide | Storage & cold chain | Myths vs facts | नेपालीमा | Clinical trials | BMI eligibility | BMI calculator | Without diabetes | Fake semaglutide warning | Ozempic & alcohol | Vs Saxenda | PCOS | Fatty liver | Kidney disease | Prediabetes | Heart health | Alternatives | Ozempic face | Hair loss | Stopping Ozempic | For men | For women | Not losing weight | Semaglutide in Nepal | GLP-1 treatment | Find a doctor | Availability | Medical weight loss | Obesity treatment | Diabetes doctor | Eligibility | Insulin resistance | Wegovy in Nepal | Mounjaro in Nepal | Rybelsus in Nepal | Areas served | Find a specialist | Weight loss medication | Book consultation | Ozempic vs keto | Vs low-carb | Vs calorie deficit | Vs exercise | Vs diet & exercise | Vs intermittent fasting | Vs fasting | Vs natural weight loss | Vs lifestyle changes | Vs medical weight mgmt | Vs dietitian-guided | Vs bariatric surgery | Request assessment
Ozempic (semaglutide) is FDA-approved for type 2 diabetes, reducing cardiovascular events in T2D patients with heart disease, and protecting kidneys in T2D with chronic kidney disease. The same molecule (as Wegovy) is approved for weight management and MASH (fatty liver disease). It is also studied for PCOS, prediabetes, heart failure, sleep apnea, and osteoarthritis.
No. Ozempic's approval is for type 2 diabetes, cardiovascular protection, and kidney protection in diabetes — but semaglutide's benefits extend to weight management, fatty liver (MASH), PCOS, prediabetes, heart failure with obesity, and more. The doctor matches the indication to your condition.
Ozempic is not FDA-approved for PCOS, but clinical trials show it helps overweight women with PCOS lose weight, improve insulin resistance, regularize menstrual cycles, and improve fertility markers. It is used off-label when a doctor judges it appropriate after assessment.
Yes — the same molecule (semaglutide, approved as Wegovy) carries an FDA indication for MASH (metabolic dysfunction-associated steatohepatitis) in patients with moderate-to-advanced liver scarring. Weight loss and metabolic improvement reduce liver fat and inflammation.
Yes — a 2025 FDA approval covers reducing the risk of kidney disease progression in type 2 diabetes patients with chronic kidney disease, based on the FLOW trial. Kidney protection is now an approved benefit, not just a side effect.
Semaglutide commonly returns elevated blood sugar to normal range in trials — STEP studies showed many prediabetic participants achieving normoglycemia. It is not approved specifically for prediabetes but may be considered when a doctor judges the benefit appropriate.
In patients with obesity-related heart failure with preserved ejection fraction (HFpEF), the STEP-HFpEF trial showed semaglutide significantly improved symptoms, exercise function, and weight. This is an evidence-backed use in the right patient group.
Weight loss from semaglutide often improves obstructive sleep apnea and knee osteoarthritis — both strongly linked to excess weight. STEP 9 trial showed reduced knee pain in obese patients with osteoarthritis. These are weight-mediated benefits discussed with your doctor.
Browse all pages